Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 13,756 matching trials from the live ClinicalTrials.gov search.
Conditions
Central Centrifugal Cicatricial Alopecia (CCCA)
Interventions
Retinoic acid, Laser, Sham treatment, Sham treatment
Drug · Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Generalized Anxiety Disorder
Interventions
PD 0332334
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
93
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Arcadia, California + 79 more
Completed No phase listed Observational Accepts healthy volunteers

Individual Differences in Reward and Impulse Control

NCT01621607
Conditions
Drug Addiction, Vulnerability to Substance Addiction
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 3 Interventional Results available

Natalizumab Re-Initiation of Dosing

NCT00306592
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BG00002 (natalizumab)
Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 46 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

NCT04334148
Conditions
COVID-19
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
Adrian Hernandez
Other
Eligibility
18 Years and older
Enrollment
1,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
34
States / cities
Aurora, Colorado • Gainesville, Florida • Jacksonville, Florida + 27 more
Conditions
Peanut Allergy
Interventions
Peanut SLIT-tablet, Placebo
Biological · Other
Lead sponsor
ALK-Abelló A/S
Industry
Eligibility
4 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
33
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more
Conditions
Solid Tumor, Pancreatic Neuroendocrine Tumor, Neuroendocrine Tumors
Interventions
PAC-1
Drug
Lead sponsor
Vanquish Oncology, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Saint Paul, Minnesota
Conditions
Heart Failure, Congestive
Interventions
Levosimendan
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
132
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 97 more
Conditions
Asthma
Interventions
Active Air Purifier, Placebo Air Purifier
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 17 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Terminated Phase 1Phase 2 Interventional Results available

Intranasal Insulin for the Treatment of HAND

NCT03081117
Conditions
HIV Dementia, HIV-Associated Cognitive Motor Complex
Interventions
Insulin, intranasal, Placebo, intranasal
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 69 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Chronic Rhinitis
Interventions
NEUROMARK System
Device
Lead sponsor
Neurent Medical
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Birmingham, Alabama • California City, California • Temecula, California + 7 more
Conditions
Falls, Sarcopenia, Obesity
Interventions
Fall prevention exercise, Health promotion education
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Allergies
Interventions
Omalizumab (Xolair®), Sodium Chloride (NaCl) 0.9 %
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more
Conditions
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
busulfan, cyclophosphamide, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
19 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
2
States / cities
Baltimore, Maryland • Columbia, South Carolina
Conditions
Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Interventions
Capecitabine, Temozolomide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
446
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 300 more
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
sargramostim
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Respicardia, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • Cincinnati, Ohio + 3 more
Conditions
Cannabis, Dependence
Interventions
THC, Rimonobant, Rimonabant
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland
Conditions
Post-COVID Postural Orthostatic Tachycardia Syndrome
Interventions
IgPro20, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 29 more
Conditions
Leukemia, Acute Myeloid (AML)
Interventions
gilteritinib, LoDAC (Low Dose Cytarabine), Azacitidine, MEC (Mitoxantrone, Etoposide, Cytarabine), FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 28 more
Conditions
Age-related Macular Degeneration
Interventions
Subcutaneous elamipretide through the elamipretide delivery system, Subcutaneos placebo through the elamipretide delivery system
Combination Product
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
55 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
37
States / cities
Peoria, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 30 more
Completed No phase listed Observational

Recovery and Outcomes From Stroke

NCT04007757
Conditions
Intracerebral Hemorrhage
Interventions
Not listed
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
8
States / cities
Chicago, Illinois • Louisville, Kentucky • Baltimore, Maryland + 5 more
Conditions
Limb Length Discrepancy
Interventions
PRECICE System
Device
Lead sponsor
Ellipse Technologies, Inc.
Industry
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
6
States / cities
Loma Linda, California • Orlando, Florida • West Palm Beach, Florida + 3 more
Terminated Not applicable Interventional Results available

Triathlon Tritanium Knee Outcomes Study

NCT02155712
Conditions
Arthroplasty, Replacement, Knee
Interventions
Triathlon Tritanium Knee, Triathlon Knee
Device
Lead sponsor
Stryker Orthopaedics
Industry
Eligibility
18 Years to 75 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
10
States / cities
Gilbert, Arizona • Tucson, Arizona • Jacksonville, Florida + 7 more